1-n-Butyl-2-methyl-5-hydroxy-indol-3-carbonsaeure | 25888-02-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-n-Butyl-2-methyl-5-hydroxy-indol-3-carbonsaeure
• 英文别名: 1-butyl-5-hydroxy-2-methyl-indole-3-carboxylic acid；1-Butyl-5-hydroxy-2-methyl-1h-indole-3-carboxylic acid；1-butyl-5-hydroxy-2-methylindole-3-carboxylic acid
• CAS: 25888-02-2
• 化学式: C₁₄H₁₇NO₃
• 分子量: 247.294
• InChiKey: VIJARGFIJBYEDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  62.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY
  申请人：Beard Richard L.

  公开号：US20070191313A1

  公开（公告）日：2007-08-16

  The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity: and wherein the variables Y, R 4 , n, A, X, Z, R 1 , o, R 3 , R 2 and p are as defined in the specification. These compounds are useful for treating a disease or condition selected from the group consisting of glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, and wound healing

  该发明提供了由式I表示的化合物，每种化合物可能具有鞘氨醇-1-磷酸受体激动剂和/或拮抗剂生物活性：其中变量Y、R4、n、A、X、Z、R1、o、R3、R2和p如规范中所定义。这些化合物对于治疗从青光眼、干眼、血管生成、心血管疾病和疾病以及伤口愈合等一组疾病或状况是有用的。
• S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION
  申请人：Allergan, Inc.

  公开号：EP2262497A2

  公开（公告）日：2010-12-22
• S1P3 RECEPTOR INHIBITORS FOR TREATING CONDITIONS OF THE EYE
  申请人：Allergan, Inc.

  公开号：EP2427189A1

  公开（公告）日：2012-03-14
• S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN
  申请人：Donello John E.

  公开号：US20100249069A1

  公开（公告）日：2010-09-30

  Disclosed herein are compositions and methods for treating pain using S1P3 receptor inhibitors.
• S1P3 Receptor Inhibitors for Treating Conditions of the Eye
  申请人：Donello John E.

  公开号：US20120071448A1

  公开（公告）日：2012-03-22

  Disclosed herein are compositions and methods for treating conditions of the eye using S1P3 receptor inhibitors.